The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of magnitude and consistency of PD-L1 expression and other variables associated with benefit from immune checkpoint inhibition (ICI): Systematic review and meta-analysis of 14 phase 3 trials in advanced gastroesophageal cancer (GEC).
 
Harry H. Yoon
Consulting or Advisory Role - ALX ONCOLOGY; Astellas Scientific and Medical Affairs Inc; AstraZeneca; BeiGene; Bristol-Myers Squibb; LSK Biopharma; Macrogenics; Merck; Zymeworks
Research Funding - Boston Biomedical (Inst); Lilly/ImClone (Inst); Merck (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Lilly
 
Zhaohui Jin
Consulting or Advisory Role - Novartis (Inst); QED Therapeutics (Inst)
 
Oudom Kour
No Relationships to Disclose
 
Kohei Shitara
Honoraria - Bristol-Myers Squibb; Takeda
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Michael K. Gibson
Consulting or Advisory Role - Abbvie; Flagship Biosciences; Soligenix
Speakers' Bureau - Bristol-Myers Squibb
 
Larry Prokop
No Relationships to Disclose
 
Yoon-Koo Kang
Consulting or Advisory Role - ALX Oncology; Amgen; Blueprint Medicines; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Macrogenics; Novartis; Surface Oncology; Zymeworks
 
Qian Shi
Stock and Other Ownership Interests - Amgen; Johnson & Johnson; Merck
Honoraria - Chugai Pharma
Consulting or Advisory Role - Boehringer Ingelheim; Hoosier Cancer Research Network; Regeneron; Yiviva
Research Funding - BMS (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Jaffer A. Ajani
Honoraria - Acrotech Biopharma; Aduro Biotech; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Pharmaceuticals; Fresenius Kabi; Gilead Sciences; GRAIL; Lilly; Merck; Novartis; oncotherics; SERVIER; zymeworks
Consulting or Advisory Role - American Cancer Society; BeiGene; Bristol-Myers Squibb; Insys Therapeutics; Merck; Vaccinogen
Research Funding - Amgen; Astellas Pharma (Inst); Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; Taiho Pharmaceutical; Takeda; Zymeworks
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly